adplus-dvertising
Connect with us

Business

‘Massive undertaking’: Roadmap of Canada’s coronavirus vaccine roll-out – Global News

Published

 on


If all goes according to plan, Canadians will start getting vaccinated for the novel coronavirus early next year.

And one of the people spearheading those efforts is a Canadian from Sherbrooke, Que. — Nicolas Chornet, senior vice-president of international manufacturing at Moderna.

Read more:
Canada will have vaccine infrastructure in place around ‘Christmas,’ 1st doses in January

He moved to Switzerland in August to set up the U.S. drugmaker’s European office and has not seen his extended family in almost a year. But they, too, ask him for constant updates.

“Hey, how fast can we get this? Because we want to see you and we want you to travel and come and see us again,’” his family asks him about the vaccine, he says.

Story continues below advertisement

According to deals signed so far, Canada could have access to up to 414 million doses of COVID-19 vaccines from seven different manufacturers.

The shipment and distribution of the vaccine — once approved — will, however, be a Herculean effort involving a lot of manpower, a web of logistical challenges and scientific constraints.


Click to play video 'Coronavirus: Majority of Canadians concerned vaccine will come too late, Ipsos poll finds'



2:29
Coronavirus: Majority of Canadians concerned vaccine will come too late, Ipsos poll finds


Coronavirus: Majority of Canadians concerned vaccine will come too late, Ipsos poll finds

Promising candidates from U.S. pharmaceutical companies Pfizer, Moderna and Johnson & Johnson as well as the U.K.’s AstraZeneca, are all currently under a rolling review process, which means vaccine data is being submitted for regulatory approval to Health Canada as it becomes available.

“Canada is one of the countries that moved very, very fast in securing a vaccine with us. It’s one of the first countries or one of the top countries to receive our supply also,” Chornet said.

Story continues below advertisement

Canada is not manufacturing any COVID-19 vaccines because it has a limited production capacity, especially for the vaccine candidates that are currently proving to be the most promising.

This means it will need to import the vaccines, adding another layer to the logistical labyrinth that has also set off political turmoil.

Read more:
Will Canada lag behind on coronavirus vaccines? It’s complicated, experts say

Last week, members of the opposition slammed Prime Minister Justin Trudeau over his comments that countries like the United States, Germany and the U.K. — some of which have domestic pharmaceutical facilities — will get vaccines before Canada.

Moderna’s supplies to Canada will come all the way from the Swiss city of Visp — home to some 8,000 people — where the company has set up a secondary production plant, in addition to its U.S. headquarters, to meet the global demand.

“Of course, our level of production or inventory will be lower than in the United States,” Chornet said, before adding: “In our distribution here (in Europe), we’ve optimized the supply chain so we can distribute as fast as possible to all the countries.”


Click to play video 'Moderna says COVID-19 vaccine 94.5% effective'



1:58
Moderna says COVID-19 vaccine 94.5% effective


Moderna says COVID-19 vaccine 94.5% effective – Nov 16, 2020

The U.S. will receive approximately 20 million doses from Moderna by the end of the year.

Story continues below advertisement

Last week, Trudeau said a majority of Canadians should be vaccinated against the coronavirus by next September. That means roughly 75 million doses for the country’s entire population if two shots are given.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

Since the start of the pandemic, more than 400,000 people in Canada have been infected and at least 12,400 have succumbed to the virus.

Long-term care homes have borne the brunt of the pandemic, with outbreaks reported at several hundred nursing homes.

More recently, hospitalizations are soaring across provinces. Quebec, Alberta and Ontario are among the worst affected.

Read more:
Canadians worry vaccine won’t come fast enough to stop coronavirus surge, Ipsos finds

A vaccine will come as a relief for lockdown-weary Canadians – 65 per cent of whom say they intend to get a vaccine when it’s approved by Health Canada and available for free, according to a new poll this week. Meanwhile, an Ipsos poll conducted exclusively for Global News found that 74 per cent of respondents are worried that the public distribution of a vaccine would be too slow to stop a greater spread of COVID-19.

The National Advisory Committee on Immunization (NACI), has identified key populations that should get immunized first, including the elderly and those with underlying health conditions, as well as health-care workers, according to its preliminary recommendations.

Story continues below advertisement

“This will probably be the most complex deployment of vaccines that we’re attempting in Canada, or I would suggest even around the world,” Daniel Chiasson, president and CEO of the Canadian Association for Pharmacy Distribution Management, told Global News.

So how will it work?

Cold storage

Both Pfizer and Moderna’s vaccines need to be kept in cold storage and have specific temperature requirements.

Pfizer’s vaccine must be shipped and stored at -70 C, while Moderna’s can be stored for up to six months at -20 C.

This requires a certain level of infrastructure that Canada may not have if vaccines are deployed in a short time frame, Chiasson said.

“The bottleneck for me is likely to be at the warehouse level,” he said.

“Do we actually have sufficient capacity with the right equipment in terms of refrigeration or frozen capacity to do it? … The infrastructure exists today. Do we have enough of it?”


Click to play video 'Pfizer-BioNTech coronavirus vaccine: The refrigeration problem no one is talking about'



1:51
Pfizer-BioNTech coronavirus vaccine: The refrigeration problem no one is talking about


Pfizer-BioNTech coronavirus vaccine: The refrigeration problem no one is talking about – Nov 10, 2020

In anticipation of a vaccine’s arrival, the federal government has ordered 26 ultra-cold freezers required for Pfizer’s vaccine and another 100 needed for Moderna’s. So far, 34 freezers have arrived, according to Public Services and Procurement Canada.

Story continues below advertisement

U.S.-based Thermo Fisher Scientific is among those companies supplying the cold storage to Canada.

Read more:
Two shots. A waiting period. Why the coronavirus vaccine won’t be a quick fix

“The criticality of this is huge, being able to manage the temperature from the point of manufacturing through distribution and ultimately to preparation for injection. It just can’t be overstated,” Dr. Alex Esman, general manager and senior director for cold storage at Thermo Fisher Scientific, told Global News.

“Typically, these freezers are used today in research… but now these freezers are going to be just in slightly different places … like in the pharmacy or in a doctor’s office or a clinical office.”

ESBE Scientific, a distribution company in Markham, Ont., told Global News it has already supplied stocks to the federal government, and the provinces of Ontario and Alberta.

Distribution

While the federal government is overseeing the procurement and authorization of the vaccines at the national level, provincial health authorities are currently working on their individual plans to decide where the vaccines will be deployed and administered and who will get them in what order.

The Canadian military has also said it is preparing to help with the country’s vaccine roll-out more broadly.

Story continues below advertisement

Read more:
Vaccine advisory committee recommends new ranked roll-out, with long-term care at top

Retired general Rick Hillier, who led the NATO forces in Afghanistan, was recently tapped to lead the vaccine roll-out for the province of Ontario.

“We’re talking to the IT professionals, they’re talking about building a system that is already in progress on iPads to use at those sites to log where the vaccines are, where they’re going to connect that to health cards to make sure that we have a record that somebody has been vaccinated,” Hillier told Global News.


Click to play video 'Coronavirus: Initial supply of COVID-19 vaccine in Canada to be around 3 million vaccinations'



1:25
Coronavirus: Initial supply of COVID-19 vaccine in Canada to be around 3 million vaccinations


Coronavirus: Initial supply of COVID-19 vaccine in Canada to be around 3 million vaccinations

At the city level, immunization teams will then be responsible for making sure the vaccines get delivered to the identified priority groups, and for carrying out the immunizations in the community.

Story continues below advertisement

Matthew Pegg, the head of Toronto’s COVID-19 Immunization Task Force, says the roll-out will be a “massive undertaking” that will require a lot of planning and co-ordination.

The “biggest hurdle,” he said, is identifying facilities that can store vaccines and serve as a location for people to get vaccinated.

“We need facilities where we can install whatever the requirements will be for refrigeration or freezers,” Pegg told Global News.

His team is currently looking for facilities to serve as warehouses for all of the expected inventory.

Second dose and followup

Vaccines from Pfizer, Moderna and AstraZeneca will require two doses.

Pfizer’s booster shot will be given three weeks after the first one, while Moderna’s is spaced four weeks later. In AstraZeneca’s clinical trials, the second dose was given a month later.

Read more:
Canada’s coronavirus vaccine roll-out — Who will get it first?

Dr. Michael Finkelstein of the Toronto Public Health says it will be important to report and investigate any adverse effects and make sure patients return for that second dose.

We have a lot of experience with people getting vaccines, but much less experience with people needing two doses,” he told Global News.

“And so it’s going to be very important for us to be able to remind people and making sure that they get the message they have to come back.”

Story continues below advertisement

If both Moderna and Pfizer’s vaccines are approved, the first batch of what’s expected to be six million doses — enough for three million Canadians — will begin arriving in early January.

But the actual work of the roll-out will be far from over.

© 2020 Global News, a division of Corus Entertainment Inc.

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Business

Roots sees room for expansion in activewear, reports $5.2M Q2 loss and sales drop

Published

 on

 

TORONTO – Roots Corp. may have built its brand on all things comfy and cosy, but its CEO says activewear is now “really becoming a core part” of the brand.

The category, which at Roots spans leggings, tracksuits, sports bras and bike shorts, has seen such sustained double-digit growth that Meghan Roach plans to make it a key part of the business’ future.

“It’s an area … you will see us continue to expand upon,” she told analysts on a Friday call.

The Toronto-based retailer’s push into activewear has taken shape over many years and included several turns as the official designer and supplier of Team Canada’s Olympic uniform.

But consumers have had plenty of choice when it comes to workout gear and other apparel suited to their sporting needs. On top of the slew of athletic brands like Nike and Adidas, shoppers have also gravitated toward Lululemon Athletica Inc., Alo and Vuori, ramping up competition in the activewear category.

Roach feels Roots’ toehold in the category stems from the fit, feel and following its merchandise has cultivated.

“Our product really resonates with (shoppers) because you can wear it through multiple different use cases and occasions,” she said.

“We’ve been seeing customers come back again and again for some of these core products in our activewear collection.”

Her remarks came the same day as Roots revealed it lost $5.2 million in its latest quarter compared with a loss of $5.3 million in the same quarter last year.

The company said the second-quarter loss amounted to 13 cents per diluted share for the quarter ended Aug. 3, the same as a year earlier.

In presenting the results, Roach reminded analysts that the first half of the year is usually “seasonally small,” representing just 30 per cent of the company’s annual sales.

Sales for the second quarter totalled $47.7 million, down from $49.4 million in the same quarter last year.

The move lower came as direct-to-consumer sales amounted to $36.4 million, down from $37.1 million a year earlier, as comparable sales edged down 0.2 per cent.

The numbers reflect the fact that Roots continued to grapple with inventory challenges in the company’s Cooper fleece line that first cropped up in its previous quarter.

Roots recently began to use artificial intelligence to assist with daily inventory replenishments and said more tools helping with allocation will go live in the next quarter.

Beyond that time period, the company intends to keep exploring AI and renovate more of its stores.

It will also re-evaluate its design ranks.

Roots announced Friday that chief product officer Karuna Scheinfeld has stepped down.

Rather than fill the role, the company plans to hire senior level design talent with international experience in the outdoor and activewear sectors who will take on tasks previously done by the chief product officer.

This report by The Canadian Press was first published Sept. 13, 2024.

Companies in this story: (TSX:ROOT)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Talks on today over HandyDART strike affecting vulnerable people in Metro Vancouver

Published

 on

 

VANCOUVER – Mediated talks between the union representing HandyDART workers in Metro Vancouver and its employer, Transdev, are set to resume today as a strike that has stopped most services drags into a second week.

No timeline has been set for the length of the negotiations, but Joe McCann, president of the Amalgamated Transit Union Local 1724, says they are willing to stay there as long as it takes, even if talks drag on all night.

About 600 employees of the door-to-door transit service for people unable to navigate the conventional transit system have been on strike since last Tuesday, pausing service for all but essential medical trips.

Hundreds of drivers rallied outside TransLink’s head office earlier this week, calling for the transportation provider to intervene in the dispute with Transdev, which was contracted to oversee HandyDART service.

Transdev said earlier this week that it will provide a reply to the union’s latest proposal on Thursday.

A statement from the company said it “strongly believes” that their employees deserve fair wages, and that a fair contract “must balance the needs of their employees, clients and taxpayers.”

This report by The Canadian Press was first published Sept. 12, 2024.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

Transat AT reports $39.9M Q3 loss compared with $57.3M profit a year earlier

Published

 on

 

MONTREAL – Travel company Transat AT Inc. reported a loss in its latest quarter compared with a profit a year earlier as its revenue edged lower.

The parent company of Air Transat says it lost $39.9 million or $1.03 per diluted share in its quarter ended July 31.

The result compared with a profit of $57.3 million or $1.49 per diluted share a year earlier.

Revenue in what was the company’s third quarter totalled $736.2 million, down from $746.3 million in the same quarter last year.

On an adjusted basis, Transat says it lost $1.10 per share in its latest quarter compared with an adjusted profit of $1.10 per share a year earlier.

Transat chief executive Annick Guérard says demand for leisure travel remains healthy, as evidenced by higher traffic, but consumers are increasingly price conscious given the current economic uncertainty.

This report by The Canadian Press was first published Sept. 12, 2024.

Companies in this story: (TSX:TRZ)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending